College of Public Health and Social Justice, Saint Louis University, St. Louis, MO, United States.
Catholic Induced Pluripotent Stem Cell Research Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Front Immunol. 2021 Mar 8;12:631291. doi: 10.3389/fimmu.2021.631291. eCollection 2021.
Mesenchymal stem cell (MSC) therapies have been used as cell-based treatments for decades, owing to their anti-inflammatory, immunomodulatory, and regenerative properties. With high expectations, many ongoing clinical trials are investigating the safety and efficacy of MSC therapies to treat arthritic diseases. Studies on osteoarthritis (OA) have shown positive clinical outcomes, with improved joint function, pain level, and quality of life. In addition, few clinical MSC trials conducted on rheumatoid arthritis (RA) patients have also displayed some optimistic outlook. The largely positive outcomes in clinical trials without severe side effects establish MSCs as promising tools for arthritis treatment. However, further research is required to investigate its applicability in clinical settings. This review discusses the most recent advances in clinical studies on MSC therapies for OA and RA.
间充质干细胞(MSC)疗法因其抗炎、免疫调节和再生特性,已被用作细胞治疗数十年。由于人们对其寄予厚望,许多正在进行的临床试验正在研究 MSC 疗法治疗关节炎疾病的安全性和有效性。针对骨关节炎(OA)的研究显示出了积极的临床结果,改善了关节功能、疼痛水平和生活质量。此外,针对类风湿关节炎(RA)患者进行的少数临床 MSC 试验也显示出了一些乐观的前景。临床试验中没有严重副作用的结果大多是积极的,这确立了间充质干细胞作为关节炎治疗有前途的工具。然而,仍需要进一步的研究来调查其在临床环境中的适用性。本文综述了 MSC 疗法治疗 OA 和 RA 的最新临床研究进展。